Cite
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
MLA
Jagannath, Sundar, et al. “Extended Follow-up of a Phase 2 Trial of Bortezomib Alone and in Combination with Dexamethasone for the Frontline Treatment of Multiple Myeloma.” British Journal of Haematology, vol. 146, no. 6, Sept. 2009, pp. 619–26. EBSCOhost, https://doi.org/10.1111/j.1365-2141.2009.07803.x.
APA
Jagannath, S., Durie, B. G. M., Wolf, J. L., Camacho, E. S., Irwin, D., Lutzky, J., McKinley, M., Potts, P., Gabayan, A. E., Mazumder, A., Crowley, J., & Vescio, R. (2009). Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology, 146(6), 619–626. https://doi.org/10.1111/j.1365-2141.2009.07803.x
Chicago
Jagannath, Sundar, Brian G. M. Durie, Jeffrey Lee Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, et al. 2009. “Extended Follow-up of a Phase 2 Trial of Bortezomib Alone and in Combination with Dexamethasone for the Frontline Treatment of Multiple Myeloma.” British Journal of Haematology 146 (6): 619–26. doi:10.1111/j.1365-2141.2009.07803.x.